3 min read
COA Research and Manufacturing Company has firmly denied allegations that its herbal product, COA-72, is being tested in clinical trials for HIV treatment. In a sharp statement, the company blamed unnamed parties and media outlets for spreading false information that could harm public trust and divert attention from scientific progress.
This issue has sparked renewed concerns about unregulated health claims in Ghana’s herbal medicine industry and highlighted the pressing need for stricter regulations.
The management of COA Research and Manufacturing Limited Company (COA-RMLC) has dismissed claims that its flagship product, COA-72, is undergoing clinical trials for HIV treatment, in response to a report published in the Daily Graphic last week.
In a statement issued Monday, the company said the report, which followed a visit by the Parliamentary Select Committee on Health to COA-RMLC’s facilities on July 14 inaccurately suggested that COA-72 was under official trial for HIV therapy.
“At no point during the meeting with the Parliamentary Select Committee did COARMLC claim that COA-72 was undergoing FDA-approved clinical trials,” the company said, clarifying that it had not received regulatory clearance from Ghana’s Food and Drugs Authority (FDA) to initiate trials.
The FDA has also issued a public disclaimer confirming that no such clinical trial has been approved, a position COA-RMLC said it supports.
COA-72 Still in Pre-Clinical Phase
COA-72, the newest product from the plant-based medicine manufacturer, is thought to have potential in fighting viral infections and certain cancers, based on internal and collaborative studies. However, the company emphasized that these findings are still preliminary and not a replacement for formal regulatory trials.
The company revealed that an application to conduct clinical trials was submitted to the FDA in 2019. While the regulator acknowledged the application and outlined the steps required to begin trials, COA-RMLC has not yet fulfilled those criteria, which include partnerships with accredited research institutions and adherence to international protocols.
No Claims of Cure, But Call for Investment
COA-RMLC emphasized that it has never claimed FDA approval for COA-72 and reiterated that none of its earlier products, including COA Mixture, COA Plus, COA-MT, and COA Capsules, are approved for HIV treatment.
“While these products are not intended or approved for HIV treatment, the research laid the foundation for the development of COA-72,” said the company’s founder and CEO, Mr. Samuel Ato Duncan, during the committee’s visit.
The company is calling for government and institutional support to enable formal clinical trials of COA-72, which it believes could contribute up to $76.8 billion annually to Ghana’s economy and generate thousands of jobs, if proven effective.
Regulatory Commitment
COA-RMLC reiterated its commitment to working within regulatory frameworks and global best practices, promising full compliance with FDA, WHO and other international health guidelines.
“We sincerely apologize for any confusion caused by the media miscommunication and hope this statement offers the needed clarity. COARMLC remains dedicated to its mission of responsibly innovating in plant-based medicine to advance public health and support national development,” the statement concluded.
Last Updated on August 16, 2025 by Samuel Kwame Boadu
Disclaimer: Some content on Accra Street Journal may be aggregated, summarized, or edited from third-party sources for informational purposes. Images and media are used under fair use or royalty-free licenses. Accra Street Journal is a subsidiary of SamBoad Publishing Hub under SamBoad Business Group Ltd, registered in Ghana since 2014.
For concerns or inquiries, please visit our Privacy Policy or Contact Page.
Samuel Kwame Boadu is a Ghanaian media entrepreneur and storyteller with a passion for amplifying urban voices and uncovering everyday truths. He is the Editor-in-Chief and Founder of Accra Street Journal, a dynamic digital platform dedicated to capturing the pulse of Ghana’s capital—its people, culture, challenges, business, sports and innovations.
Use the following reference when citing or referencing this article.
Your feedback helps us improve our journalism.
Report an Error
Help us maintain accuracy. Let our editorial team know if you spot an issue in this article.




